US 7,320,991 B2 | ||
Analogs of thalidomide as potential angiogenesis inhibitors | ||
William D. Figg, Fairfax, Va. (US); Kurt Eger, Leipzig (Germany); Uwe Teubert, Hameln (Germany); Michael Weiss, Bethesda, Md. (US); Michael Guetschow, Bonn (Germany); Thomas Hecker, Erfurt (Germany); and Sunna Hauschildt, Leipzig (Germany) | ||
Assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Washington, D.C. (US) | ||
Appl. No. 10/469,359 PCT Filed Feb. 26, 2002, PCT No. PCT/US02/05868 § 371(c)(1), (2), (4) Date Nov. 14, 2003, PCT Pub. No. WO02/068414, PCT Pub. Date Sep. 06, 2002. |
||
Claims priority of provisional application 60/271941, filed on Feb. 27, 2001. | ||
Prior Publication US 2004/0077685 A1, Apr. 22, 2004 | ||
Int. Cl. A61K 31/445 (2006.01) |
U.S. Cl. 514—323 | 9 Claims |
1. A method of inhibiting angiogenesis in a subject having unwanted angiogenesis, comprising:
administering to the subject a therapeutically effective amount of one or more compounds selected from the group consisting
of the following compounds, and mixtures thereof or pharmaceutically acceptable salts thereof:
![]() wherein R4 through R7 are, independently, a halogen, or R5 and R6 are hydrogen and R4 and R7 are methyl groups.
|